Literature DB >> 19848607

Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection.

Marija Zeremski1, Rositsa Dimova, Queenie Brown, Ira M Jacobson, Marianthi Markatou, Andrew H Talal.   

Abstract

BACKGROUND: CXCR3-associated chemokines CXCL9-CXCL11 promote histologic progression in chronic hepatitis C virus (HCV) infection, as indicated by elevated intrahepatic levels of messenger RNA in patients with advanced inflammation and fibrosis. We evaluated the potential of peripheral chemokine levels to discriminate among patients with chronic HCV infection who had different stages of fibrosis.
METHODS: Peripheral levels of CXCR3-associated chemokines were measured by enzyme-linked immunosorbent assay of plasma samples obtained from 93 patients with chronic HCV infection. Of the subjects, 79 (85%) were white, and 68 (73%) were infected with HCV genotype 1.
RESULTS: Expression of all 3 chemokines, when analyzed as a group, was significantly associated with intrahepatic inflammation and fibrosis. Plasma levels of CXCL10 were significantly elevated in patients with advanced fibrosis, whereas CXCL9 levels were significantly elevated in patients with advanced inflammation. By proportional odds multivariate modeling, we observed an association between fibrosis and CXCL10 (P< .002) as well as between fibrosis and inflammation (P<.001). Of the individual parameters, the CXCL10 level was most useful in identifying patients with more-severe (stage 3-4) fibrosis. Discriminatory ability was improved by the combination of CXCL10 and CXCL9.
CONCLUSIONS: The strong association between CXCR3-associated chemokines and fibrosis suggests that they may have promise as noninvasive markers of hepatic fibrosis in a predominantly white HCV genotype 1-infected population.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19848607     DOI: 10.1086/646614

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  46 in total

1.  Detection of host immune responses in acute phase sera of spontaneous resolution versus persistent hepatitis C virus infection.

Authors:  Suganya Selvarajah; Sheila Keating; John Heitman; Kai Lu; Graham Simmons; Philip J Norris; Eva Operskalski; James W Mosley; Michael P Busch
Journal:  J Gen Virol       Date:  2012-04-25       Impact factor: 3.891

Review 2.  Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells.

Authors:  Barbara Rehermann
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

3.  Innate immune response to influenza A virus in differentiated human alveolar type II cells.

Authors:  Jieru Wang; Mrinalini P Nikrad; Tzulip Phang; Bifeng Gao; Taylor Alford; Yoko Ito; Karen Edeen; Emily A Travanty; Beata Kosmider; Kevan Hartshorn; Robert J Mason
Journal:  Am J Respir Cell Mol Biol       Date:  2011-01-14       Impact factor: 6.914

4.  Profibrogenic chemokines and viral evolution predict rapid progression of hepatitis C to cirrhosis.

Authors:  Patrizia Farci; Kurt Wollenberg; Giacomo Diaz; Ronald E Engle; Maria Eliana Lai; Paul Klenerman; Robert H Purcell; Oliver G Pybus; Harvey J Alter
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-24       Impact factor: 11.205

5.  Interferon γ-induced protein 10 kinetics in treatment-naive versus treatment-experienced patients receiving interferon-free therapy for hepatitis C virus infection: implications for the innate immune response.

Authors:  Jennifer C Lin; François Habersetzer; Maribel Rodriguez-Torres; Nezam Afdhal; Eric J Lawitz; Matthew S Paulson; Yanni Zhu; Gangadharan Mani Subramanian; John G McHutchison; Mark Sulkowski; David L Wyles; Robert T Schooley
Journal:  J Infect Dis       Date:  2014-06-06       Impact factor: 5.226

6.  Twelve potential fibrosis markers to differentiate mild liver fibrosis from cirrhosis in patients infected with chronic hepatitis C genotype 1.

Authors:  E S Andersen; M Ruhwald; B Moessner; P B Christensen; O Andersen; J Eugen-Olsen; N Weis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-01-13       Impact factor: 3.267

7.  Induction of CXCR3- and CCR5-associated chemokines during acute hepatitis C virus infection.

Authors:  Marija Zeremski; Giles Hooker; Marla A Shu; Emily Winkelstein; Queenie Brown; Don C Des Jarlais; Leslie H Tobler; Barbara Rehermann; Michael P Busch; Brian R Edlin; Andrew H Talal
Journal:  J Hepatol       Date:  2011-01-21       Impact factor: 25.083

8.  Clinical significance and functional studies of myeloid-derived suppressor cells in chronic hepatitis C patients.

Authors:  Weiping Cai; Aiping Qin; Pengle Guo; Dehong Yan; Fengyu Hu; Qiong Yang; Min Xu; Yongshui Fu; Jie Zhou; Xiaoping Tang
Journal:  J Clin Immunol       Date:  2013-01-26       Impact factor: 8.317

9.  Inhibition of the CXCL12/CXCR4 chemokine axis with AMD3100, a CXCR4 small molecule inhibitor, worsens murine hepatic injury.

Authors:  Yedidya Saiman; JingJing Jiao; M Isabel Fiel; Scott L Friedman; Costica Aloman; Meena B Bansal
Journal:  Hepatol Res       Date:  2014-10-07       Impact factor: 4.288

10.  Parallel increase of circulating CXCL11 and CXCL10 in mixed cryoglobulinemia, while the proinflammatory cytokine IL-6 is associated with high serum Th2 chemokine CCL2.

Authors:  Alessandro Antonelli; Poupak Fallahi; Silvia Martina Ferrari; Alda Corrado; Marco Sebastiani; Dilia Giuggioli; Mario Miccoli; Anna Linda Zignego; Domenico Sansonno; Santino Marchi; Clodoveo Ferri
Journal:  Clin Rheumatol       Date:  2013-04-05       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.